Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Jan Steffel,
As expected, there were hardly any seats left in the session “New oral anticoagulants / clinical challenges” due to the timeliness of the topic and the list of high ranking speakers. Chaired by Dr. Steffel (Zurich, Switzerland) and Dr. Andreotti (Rome/Italy), Dr. Ottani (Piangipane/Italy) started off the session by explaining the necessity of, and summarizing the modalities for bleeding risk stratification.
Dr. Svensson from Malmo (Sweden) continued on the possibilities of monitoring new oral anticoagulants (NOACs) with a specific emphasis on situations in which it makes sense to do so – and when not. Using 4 patient case scenarios, Dr. Halvorsen (Oslo, Norway) explained the management of patients undergoing percutaneous coronary interventions or electrophysiological testing, with a special note on peri-interventional anticoagulation regimens and the necessity for triple anticoagulation. Finally, Dr. Verheugt from Amsterdam (Netherlands) explained management issues in patients undergoing major and/or urgent surgical procedures, thereby also touching on the possibilities as well as limitations and risks of antagonizing anticoagulation therapy (both vitamin K antagonists as well as NOACs).
Lively discussion amongst the audience, chairpersons and speakers reflected both the high interest in these novel substances, and the desire to use them correctly – even in tricky situations – to maximize patient benefit.
New oral anticoagulants - clinical challenges